Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
by Zacks Equity Research
Alexion (ALXN) has finally announced the filing of its Form 10-Q with the SEC for the period ended Sep 30, 2016 and retained its outlook for 2016.
Alexion (ALXN): Will the Stock Continue to Suffer in 2017?
by Zacks Equity Research
Given the delay in filing the 10-Q, departure of key executives, pipeline setbacks and the ongoing drug pricing issues, Alexion seems to be heading toward difficult times in 2017.
Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
by Arpita Dutt
Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
by Arpita Dutt
We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe
by Zacks Equity Research
Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.
Alexion Presents Data from Ultra-Rare Blood Disorder Study
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.
Top Research Reports for Celgene, Ford & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (DOW), Celgene (CELG), and Ford (F).
Stock Market News for June 16, 2016
by Zacks Equity Research
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year